Year: 2008
Type: review
Abstract: Cytokines are a large family of more than 100 small proteins that function as short-range mediators involved in essentially all biological processes.They have been found to be important rate-limiting signals, and it is now known that blocking some cytokines, e.g., TNF-α, and cytokine receptors, such as human EGFR 1 (HER1) or HER2, yields effective therapeutics that address unmet needs.This Review Series surveys three chronic inflammatory disease areas and two forms of cancer and discusses the important role of cytokines and their receptors in these disease processes.Their role as potential therapeutic targets is also highlighted.Cytokines, low-MW protein mediators that usually act at short range between neighboring cells, have been studied extensively for the past 30 years.These molecules, previously also termed interleukins, interferons, growth factors, and TNFs, among other designations, are involved in essentially every important biological process, from cell proliferation to inflammation, immunity, migration, fibrosis, repair, and angiogenesis (1, 2).As these molecules and their associated receptors provide key signals for important processes, it is not surprising that abnormalities in cytokines, their receptors, and the signaling pathways that they initiate are involved in a wide variety of diseases.Indeed, they have a role in far too many diseases for each to be covered in this Review Series.Rather, representative examples of the cytokines involved in some forms of cancer and immune and inflammatory diseases are discussed.The critical issue in each case is the importance of cytokines as therapeutic targets, and the overwhelming message is that "anti-cytokine medicine" is a rapidly growing field with major pharmaceutical impact. Cytokines: from identification to the clinicThe field of cytokines came of age in the late 1970s with the introduction of molecular biological approaches that resulted first in the cloning of IFNs, initially IFN-β by Tada Taniguchi (3) and IFN-α by both Charles Weissman's group and David Goeddel's colleagues (4, 5).By the mid-1980s, there was a plethora of well-defined cytokines and cytokine receptors that could be unambiguously studied, using molecular tools, such as cDNA probes, and antibodies that had been produced to recognize the pure recombinant proteins.All this was a long way from the 1960s and 1970s, when all researchers had were many uncharacterized bioactivities in cell supernatants termed simply by activity, e.g., lymphocyte-activating factor (6), macrophageactivating factor (7), and leukocyte pyrogen (8).All the tools available by the mid-1980s enabled researchers to assess the expression of cytokines in physiologic and patho-Nonstandard abbreviations used: AD, Alzheimer disease; CML, chronic myelogenous leukemia; COPD, chronic obstructive pulmonary disease; HER, human EGFR.
DOI: 10.1172/jci37346
Author: Marc Feldmann
Institution: Imperial College London
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
Funder: Celgene
OpenAlex ID: W2019137678
